Nordic HSCT Complication Symposium
You are invited to join this Nordic webinar where leading experts will present the latest knowledge about HSCT Complications.
The webinar takes place Wednesday, November 10th, 2021
15.00 - 17.30, Central European Time - CET (Denmark, Norway and Sweden)
16.00 - 18.30 Eastern European Time – EET (Finland)
Participation is free of charge for doctors and other healthcare professionals.
|15.00 - 15.05 CET
By Tapani Ruutu, former head of the Helsinki transplant unit for adults and chair of the early transplant complications subcommittee of the EBMT
|15.05 - 15.30 CET
||Treatment of refractory acute GvHD
Steroid refractory acute GvHD remains a significant obstacle to successful allogeneic stem cell transplantation with a high risk of treatment related morbidity when it occurs. The presentation will discuss current concepts and novel approaches in prevention of GvHD and treatment of steroid refractory and steroid dependant acute GvHD.
By Yngvar Floisand, MD PhD, Consultant Haematologist, Clinical Research Lead for Haemato-oncology, Associate Programme Director for Stem Cell Transplantation and Cellular Therapies, The Clatterbridge Cancer Centre NHS Foundation Trust
|15.30 - 15.40 CET
|15.40 - 16.05 CET
||Sinosoidal Obstructive Syndrome – clinical and basic aspects
This presentation will cover basic as well as clinical and therapeutic aspects of SOS, including the challenges related to various sets of diagnostic criteria that have been proposed. Finally, we will present some recent research data that add to our understanding of the well-known large individual differences in the sensitivity of our patients to toxic-inflammatory side effects of chemotherapy of relevance for SOS.
By Klaus Müller, Professor, Head Physician, MD, Pediatric Department at Rigshospitalet, Copenhagen Denmark
|16.05 - 16.15 CET
|16.15 - 16.40 CET
||Novel aspects in the diagnosis and treatment of transplant-associated microangiopathy
The presentation will cover the differences in the existing diagnostic criteria, additional laboratory methods to support the diagnosis, existing treatment approaches, including immunosuppression manipulation, anti-complement therapies, phosphodiester oligonucleotides, as well as response definitions and long-term outcomes.
By Ivan Moiseev, MD, PhD at St. Petersburg State Pavlov Medical University and Secretary of the Transplant Complications Working Party of the EBMT
|16.40 - 16.50 CET
|16.50 - 17.15 CET
||COVID-19 in HCT and CAR T cell recipients
The COVID-19 pandemic has resulted in high morbidity and mortality among patients belonging to risk groups such as those with hematological malignancies. Despite advances in management and the unprecedented introduction of vaccines, several problems still remain, when we are possibly facing a 4th wave. This talk will review outcome of COVID-19 in these patient groups and discuss possibilities and problems with vaccination.
By Per Ljungman, MD, PhD, Professor (em) of hematology, Division of Hematology, Dept. of Medicine Huddinge Karolinska Institutet, Senior physician Dept. of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska Comprehensive Cancer Center, Karolinska University Hospital Huddinge, Stockholm, Sweden
|17.15 - 17.25 CET
|17.25 - 17.30 CET
||Thank you for today
By Tapani Ruutu
Medicinske Tidsskrifter has applied for and obtained sponsorship support to complete the meeting from Jazz Pharmaceutical. Therefore, participation is without charge for doctors and other healthcare professionals.
|Event Date||11-10-2021 3:00 pm|
|Event End Date||11-10-2021 5:30 pm|